Document Detail


From differences in means between cases and controls to risk stratification: a business plan for biomarker development.
MedLine Citation:
PMID:  23299199     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
SIGNIFICANCE: Many efforts go into futile biomarker development and premature clinical testing. In many instances, predictions for translational success or failure can be made early, simply based on critical analysis of case–control data. Our article presents well-established theory in a form that can be appreciated by biomarker researchers. Furthermore, we provide an interactive spreadsheet that links biomarker performance with specific disease characteristics to evaluate the promise of biomarker candidates at an early stage.
Authors:
Nicolas Wentzensen; Sholom Wacholder
Related Documents :
2260789 - Radioactivity in human milk.
23391059 - Do researchers have an obligation to actively look for genetic incidental findings?
14590169 - Low-level lead exposure and intelligence in children.
23447409 - The role of the institutional review board in the oversight of the ethical aspects of h...
14621879 - Is tolerance a prospective for clinical research?
368819 - Prejudices in pharmacology and pharmacotherapy: reserpine as a model for experimental r...
20330459 - Recommendations for the improvement of the management of noise from helicopter operations.
25487039 - Persistence of phlebotomine leishmania vectors in urban sites of catania (sicily, italy).
24476999 - Right answers, wrong questions in clinical research.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Intramural; Review     Date:  2013-01-08
Journal Detail:
Title:  Cancer discovery     Volume:  3     ISSN:  2159-8290     ISO Abbreviation:  Cancer Discov     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-02-12     Completed Date:  2013-08-20     Revised Date:  2014-02-04    
Medline Journal Info:
Nlm Unique ID:  101561693     Medline TA:  Cancer Discov     Country:  United States    
Other Details:
Languages:  eng     Pagination:  148-57     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Biomedical Research / methods
Early Diagnosis
Humans
Neoplasms / diagnosis*,  prevention & control*
ROC Curve
Reproducibility of Results
Research Design*
Risk Assessment / methods
Risk Factors
Tumor Markers, Biological / analysis*
Grant Support
ID/Acronym/Agency:
ZIA CP010124-16/CP/NCI NIH HHS; ZIA CP010124-17/CP/NCI NIH HHS; ZIA CP010181-08/CP/NCI NIH HHS; ZIA CP010181-09/CP/NCI NIH HHS; ZIA CP010181-10/CP/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Tumor Markers, Biological
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  C-kit-mutated melanomas: the Chinese experience.
Next Document:  Flexible CuS nanotubes-ITO film Schottky junction solar cells with enhanced light harvesting by usin...